Alliance Pharma

www.alliancepharma.co.uk News

Alliance Pharma RNS Press Releases

16/01/12

16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".

16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".
16/01/12

16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".

16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".
17/11/11
+0.00 +29.50

Collins Stewart initiates buy on Alliance Pharma, target price 36p.

Collins Stewart initiates buy on Alliance Pharma, target price 36p.
18/10/11
+0.00 +30.50

Investec initiates buy on Alliance Pharma.

Investec initiates buy on Alliance Pharma.
06/07/11
+0.88 +27.88

Numis upgrades Alliance Pharma from hold to buy, target price unchanged at 37p.

Numis upgrades Alliance Pharma from hold to buy, target price unchanged at 37p.

Alliance Pharma Articles

08/12/11

Alliance Pharma’s business model “misunderstood” by stock market, says Investec

The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors
17/11/11

Alliance Pharma is “a stock for the times”, says Collins Stewart

The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy
07/09/11

Alliance Pharma’s interim results demonstrate strong underlying sales growth

Steady sales growth among non-Deltacortril products and the prospect of further acquisitions has led house broker Numis to set a price target of 37 pence each for Alliance’s shares
20/07/11

Alliance Pharma: Acquisition strategy continues to pay off

Alliance Pharma focuses on speciality drugs and treatments for a range of health issues. The firm has been highly acquisitive since it was founded in 1998 and in recent years this acquisition strategy has paid off in terms of both revenue and profit. Here, we take a close look at the business
06/07/11

Alliance Pharma a 'buy’ after trading statement, says Numis

Numis and FinnCap both rate Alliance Pharma's shares as a 'buy' after Alliance said first-half sales would be £1 million ahead of H1 2010. Numis has set a target price of 37 pence for the shares

Alliance Pharma market reports

Date	Director	Trans	Amount	Type	Price(p)	Value (£)	Holding	%
16/09/11	R. Wright	EX	136,376	OPT	8.25	11,251	0,000	N/A
16/09/11	R. Wright	EX	463,624	OPT	8.50	39,408	0,000	N/A
16/09/11	R. Wright	SELL	600,000	ORD	30.50	183,000	190,768	0.08
06/05/11	A.R. Booley	EX	1,110,000	OPT	8.50	94,350	0,000	N/A
06/05/11	A.R. Booley	SELL	1,110,000	ORD	33.00	366,300	6,810,723	2.85

BASIC RESULTS INFORMATION

Date	Type	Turnover	Profit	EPS (p)	Dividend (p)	Currency
31/12/11	Full year	45.96	10.71	3.62	0.75	GBX
30/06/11	Interim	24.39	7.00	2.38	0.25	GBX
31/12/10	Full year	49.88	12.87	3.96	0.57	GBX
30/06/10	Interim	23.36	5.97	1.97	0.17	GBX
31/12/09	Full year	31.24	5.74	2.37	0.30	GBX

Currency	Ex-Date	Pay Date	Net Dividend	Currency	Total for year
H2 Dividend	13/06/12	12/07/12	0.5000	GBX	0.7500
H1 Dividend	30/11/11	13/01/12	0.2500	GBX
H2 Dividend	15/06/11	14/07/11	0.4000	GBX	0.5700
H1 Dividend	01/12/10	14/01/11	0.1700	GBX
H2 Dividend	16/06/10	15/07/10	0.2300	GBX

Additional Information

Share Price

29.00p

Change

-0.38

Volume

159,000

Dividend

0.75

EPS

3.96

Shares

240.6 m

Offer

29.25

Bid

28.75

Avg. Vol

532,147

Yield

0.83

P/E

7.32

Mkt Cap

69.8 m
Latest Stocktube

30/03/2012
Alliance Pharma CEO looks forward to continued good growth prospects
View full size
People interested in this company also viewed
ProactiveInvestors on Facebook

LOGIN